TVTX — Travere Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.98bn
- $5.09bn
- $490.73m
Brief: Travere Therapeutics Q3 EPS USD -0.7 Vs. IBES Estimate USD -0.66
Brief: Travere Therapeutics And CSL Vifor Announce Swissmedic Approval Of FILSPARI For Treatment Of IgA Nephropathy
U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink
U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International
Travere falls after pausing genetic disorder drug study
Travere Therapeutics falls on pausing enrollment in trial for inherited disorder drug
Brief: Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
U.S. RESEARCH ROUNDUP-Apple, Fedex, Vaxcyte
U.S. STOCKS ON THE MOVE-Teekay, Brenmiller Energy, JetBlue
U.S. STOCKS ON THE MOVE-Teekay, Brenmiller Energy, JetBlue
Travere Therapeutics rises as Guggenheim upgrades to 'buy'
U.S. STOCKS ON THE MOVE-Smartsheet, Bowlero, Samsara
U.S. STOCKS ON THE MOVE-Planet Labs, Broadcom, Bloom Energy
Travere Therapeutics rises on US FDA's full approval for kidney disease therapy
Brief: Travere Therapeutics Announces Full FDA Approval Of Filspari®
US FDA approves Novartis' kidney disease drug (updated)
US FDA approves Novartis' kidney disease drug
Travere Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Travere Therapeutics Q2 EPS USD -0.91 Vs. IBES Estimate USD -0.86